menu
    • menu
    [{"orgOrder":0,"company":"Vaximm AG","sponsor":"NEC OncoImmunity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2022","type":"Acquisition","leadProduct":"NECVAX-NEO1","moa":"Cytotoxic T-cell","graph1":"Oncology","graph2":"Preclinical","graph3":"Vaximm AG","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaximm AG \/ NEC OncoImmunity","highestDevelopmentStatusID":"4","companyTruncated":"Vaximm AG \/ NEC OncoImmunity"},{"orgOrder":0,"company":"Vaximm AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2011","type":"Inapplicable","leadProduct":"VXM01","moa":"VEGFR-2","graph1":"Oncology","graph2":"Phase I","graph3":"Vaximm AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Vaximm AG \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vaximm AG \/ Undisclosed"},{"orgOrder":0,"company":"Vaximm AG","sponsor":"Merck Group | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2018","type":"Inapplicable","leadProduct":"VXM01","moa":"VEGFR-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vaximm AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaximm AG \/ Merck Group | Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Vaximm AG \/ Merck Group | Pfizer Inc"},{"orgOrder":0,"company":"Vaximm AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2016","type":"Inapplicable","leadProduct":"VXM01","moa":"VEGFR-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vaximm AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaximm AG \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Vaximm AG \/ Undisclosed"},{"orgOrder":0,"company":"Vaximm AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2016","type":"Inapplicable","leadProduct":"VXM01","moa":"VEGFR-2","graph1":"Oncology","graph2":"Phase I","graph3":"Vaximm AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaximm AG \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vaximm AG \/ Undisclosed"},{"orgOrder":0,"company":"Vaximm AG","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"VXM01","moa":"||VEGFR-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vaximm AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaximm AG \/ Merck Group","highestDevelopmentStatusID":"7","companyTruncated":"Vaximm AG \/ Merck Group"}]

    Find Clinical Drug Pipeline Developments & Deals by Vaximm AG

    Menu

    Vaximm AG

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Vaximm AG

                            Switzerland arrow
                            Neuroscience
                            Not Confirmed

                            Vaximm AG

                            Switzerland arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VXM01,Avelumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Merck Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vaximm Shares VXM01-Avelumab Combo Results in Glioblastoma

                            Details : VXM01 is an investigational oral anti-VEGFR-2 vaccine, which is being evaluated in combination with avelumab (PD-L1 inhibitor) for treating patients with recurrent glioblastoma.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            March 26, 2025

                            Lead Product(s) : VXM01,Avelumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Merck Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Vaximm AG

                            Switzerland arrow
                            Neuroscience
                            Not Confirmed

                            Vaximm AG

                            Switzerland arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NECVAX-NEO1

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : NEC OncoImmunity

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            NEC OncoImmunity Acquires VAXIMM's Neoantigen Vaccine Development Assets

                            Details : Under the agreement, NOI will acquire VAXIMM’s neoantigen vaccine-related patents including VXM01, which is being developed for the treatment of glioblastoma, license the requisite manufacturing patents, and will take over existing contracts with colla...

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            March 08, 2022

                            Lead Product(s) : NECVAX-NEO1

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : NEC OncoImmunity

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Vaximm AG

                            Switzerland arrow
                            Neuroscience
                            Not Confirmed

                            Vaximm AG

                            Switzerland arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VXM01

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Merck Group | Pfizer Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma

                            Details : VXM01 is a Vaccine drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Glioblastoma.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            November 21, 2018

                            Lead Product(s) : VXM01

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Merck Group | Pfizer Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Vaximm AG

                            Switzerland arrow
                            Neuroscience
                            Not Confirmed

                            Vaximm AG

                            Switzerland arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VXM01

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma

                            Details : VXM01 is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Glioblastoma.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            March 24, 2016

                            Lead Product(s) : VXM01

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Vaximm AG

                            Switzerland arrow
                            Neuroscience
                            Not Confirmed

                            Vaximm AG

                            Switzerland arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VXM01

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            VXM01 Phase I Study in Patients With Metastatic Colorectal Cancer With Liver Metastasis

                            Details : VXM01 is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Colorectal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            March 24, 2016

                            Lead Product(s) : VXM01

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Vaximm AG

                            Switzerland arrow
                            Neuroscience
                            Not Confirmed

                            Vaximm AG

                            Switzerland arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VXM01

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Canc...

                            Details : VXM01 is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pancreatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            December 06, 2011

                            Lead Product(s) : VXM01

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth